Bloom Burton analyst David Martin PhD has maintained their bullish stance on DHT.UN stock, giving a Buy rating on July 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Martin PhD has given his Buy rating due to a combination of factors influencing DRI Healthcare’s financial outlook. Despite a year-over-year decline in Vonjo’s net sales, attributed largely to changes in U.S. reimbursement policies, the demand for the drug has actually increased, as evidenced by an 11% rise in volume sales. This suggests a strong underlying demand that could translate into future revenue growth once pricing pressures stabilize.
Additionally, DRI Healthcare benefits from higher royalty rates on Vonjo compared to other products like Aspaveli/Empaveli, which experienced a 21% increase in net sales. The substantial royalty income from Vonjo, despite current challenges, positions DRI Healthcare favorably for long-term profitability. These factors combined provide a solid foundation for the Buy rating, indicating confidence in the company’s ability to navigate current market challenges and capitalize on future opportunities.
In another report released on July 10, Stifel Nicolaus also maintained a Buy rating on the stock with a C$19.00 price target.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DHT.UN in relation to earlier this year.